Chronic beta-adrenergic antagonist treatment affects human T lymphocyte responsiveness "in vitro".
The aim of the present study was the evaluation of the effect of long-term propranolol treatment on some immune parameters in humans. The subjects were 12 duodenal ulcer patients, aged 19-23 years. They were given propranolol in a dose of 40 mg three times a day orally. Blood samples were drawn before and after one-month propranolol treatment. The drug did not significantly affect mitogen (PHA, Con A, PWM)- induced lymphoproliferative response, although a tendency of a slight inhibition of proliferation was observed. In all patients treated with propranolol absolute peripheral blood lymphocyte counts increased. Propranolol did not significantly influence one-way MLR, while it enhanced proliferation in the AMLR test in all patients. The drug increased spontaneous and PHA-induced IL-2R expression as well as IL-2 generation. The study showed that chronic beta-adrenoceptor blockade with propranolol may modify some immune functions in humans.
Malec
P H
PH
Department of Cardiology, School of Medicine, Lódz, Poland.
Zeman
K
K
Markiewicz
K
K
Tchórzewski
H
H
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000328:Adult; D004381:Duodenal Ulcer / Q000097:blood / Q000188:drug therapy; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007376:Interleukin-2 / Q000096:biosynthesis; D008213:Lymphocyte Activation / Q000187:drug effects; D007959:Lymphocyte Culture Test, Mixed; D008297:Male; D011433:Propranolol / Q000008:administration & dosage / Q000494:pharmacology; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology
D000319:Adrenergic beta-Antagonists; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D011433:Propranolol